Annual report pursuant to Section 13 and 15(d)

Note 4 - Revenue From Contracts With Customers (Tables)

v3.19.1
Note 4 - Revenue From Contracts With Customers (Tables)
 12 Months Ended
Dec. 31, 2018
Notes Tables  
Disaggregation of Revenue [Table Text Block]
Year
Ended
Dec
ember 3
1
, 2018
  
Diagnostics
    
Therapeutics
    
Total
  
Royalty revenue:
                        
Europe
   $
15,347
     $
—
     $
15,347
  
India
    
—
      
—
      
—
  
China
    
—
      
—
      
—
  
Total
   $
15,347
     $
—
     $
15,347
  
                         
License revenue:
                        
NAV4694 sublicense
   $
287,569
     $
—
     $
287,569
  
Tc99m tilmanocept sublicense, China
    
19,605
      
—
      
19,605
  
Total
   $
307,174
     $
—
     $
307,174
  
                         
Other revenue:
                        
Additional stability studies
   $
15,037
     $
—
     $
15,037
  
Contract with Customer, Asset and Liability [Table Text Block]
   
Year
Ended
Dec
ember 3
1
,
  
   
2018
    
2017
  
Total deferred revenue, beginning of period
   $
26,061
     $
41,098
  
Impact of adoption of ASU 2014-09 and related standards
    
700,000
      
—
  
Revenue deferred related to sublicense
    
10,000
      
—
  
Revenue recognized from satisfaction of performance obligations
    
(25,037
)
    
(15,037
)
Total deferred revenue, end of period
   $
711,024
     $
26,061
  
Accounting Standards Update 2014-09 [Member]  
Notes Tables  
Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]
   
Pre-
Adoption
    
Post-Adoption
    
Change
  
Deferred revenue
   $
26,061
     $
726,061
     $
700,000
  
Accumulated deficit
    
(319,908,968
)
    
(320,608,968
)
    
(700,000
)